scholarly journals Pitfalls and Caveats in Applying Immunostaining to Histopathological Diagnosis

2021 ◽  
Author(s):  
Yutaka Tsutsumi
Keyword(s):  
Target Therapy ◽  
Molecular Target ◽  
Review Article ◽  
Present Review ◽  
Technical Development ◽  
Histopathological Diagnosis ◽  
Histochemical Technique ◽  
Molecular Target Therapy ◽  
Trouble Shooting ◽  
Immunohistochemical Markers

Immunostaining is an essential histochemical technique for analyzing pathogenesis and making a histopathological diagnosis. The needs are prompted by technical development and refinement, commercial availability of a variety of antibodies, deepened knowledge of immunohistochemical markers, accelerated analysis of morphofunctional correlations, progress in molecular target therapy, and the expectation of advanced histopathological diagnosis. However, immunostaining does have various pitfalls and caveats. We should learn from mistakes and failures, as well as from false positivity and false negativity. The present review article describes various devices, technical hints and trouble-shooting guides to keep in mind in performing immunostaining.

scholarly journals Pitfalls and Caveats in Applying Chromogenic Immunostaining to Histopathological Diagnosis

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1501
Author(s):  
Yutaka Tsutsumi
Keyword(s):  
Review Article ◽  
Behavioral Characteristics ◽  
Histopathological Diagnosis ◽  
Histochemical Technique ◽  
Biological Features ◽  
Trouble Shooting ◽  
Immunohistochemical Markers ◽  
Neoplastic Lesions ◽  
Clinicopathological Correlations ◽  
Labeled Probe

Chromogenic immunohistochemistry (immunostaining using an enzyme-labeled probe) is an essential histochemical technique for analyzing pathogenesis and making a histopathological diagnosis in routine pathology services. In neoplastic lesions, immunohistochemistry allows the study of specific clinical and biological features such as histogenesis, behavioral characteristics, therapeutic targets, and prognostic biomarkers. The needs for appropriate and reproducible methods of immunostaining are prompted by technical development and refinement, commercial availability of a variety of antibodies, advanced applicability of immunohistochemical markers, accelerated analysis of clinicopathological correlations, progress in molecular targeted therapy, and the expectation of advanced histopathological diagnosis. However, immunostaining does have various pitfalls and caveats. Pathologists should learn from previous mistakes and failures and from results indicating false positivity and false negativity. The present review article describes various devices, technical hints, and trouble-shooting guides to keep in mind when performing immunostaining.

scholarly journals Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

2013 ◽  
Vol 14 (1) ◽  
pp. 15-26 ◽  
Author(s):  
Christian Rolfo ◽  
Luis E Raez ◽  
Antonio Russo ◽  
Noemí Reguart ◽  
Rosario García Campelo ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy ◽  
New Era

Possible molecular target therapy with rapamycin in MDS

2006 ◽  
Vol 47 (5) ◽  
pp. 907-911
Author(s):  
Yasuhiro Maeda ◽  
Terufumi Yamaguchi ◽  
Yasuki Hijikata ◽  
Toshiaki Matsuoka ◽  
Miyako Tanaka ◽  
...  
Keyword(s):  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

scholarly journals Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2875
Author(s):  
Yoshiyuki Matsui
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastasis ◽  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

In patients with renal cell carcinoma, brain metastasis is generally one of the poor prognostic factors. However, the recent introduction of molecular target therapy and immune checkpoint inhibitor has remarkably advanced the systemic treatment of metastatic renal cell carcinoma and prolonged the patients’ survival. The pivotal clinical trials of those agents usually excluded patients with brain metastasis. The incidence of brain metastasis has been increasing in the actual clinical setting because of longer control of extra-cranial disease. Brain metastasis subgroup data from the prospective and retrospective series have been gradually accumulated about the risk classification of brain metastasis and the efficacy and safety of those new agents for brain metastasis. While the local treatment against brain metastasis includes neurosurgery, stereotactic radiosurgery, and conventional whole brain radiation therapy, the technology of stereotactic radiosurgery has been especially advanced, and the combination with systemic therapy such as molecular target therapy and immune checkpoint inhibitor is considered promising. This review summarizes recent progression of multimodality treatment of brain metastasis of renal cell carcinoma from literature data and explores the future direction of the treatment.

Molecular target therapy for synovial sarcoma

2005 ◽  
Vol 1 (6) ◽  
pp. 805-812 ◽  
Author(s):  
Chikako Fukukawa ◽  
Yusuke Nakamura ◽  
Toyomasa Katagiri
Keyword(s):  
Synovial Sarcoma ◽  
Target Therapy ◽  
Molecular Target ◽  
Molecular Target Therapy

A case of advanced melanoma treated with molecular target therapy and immune checkpoint inhibitors

Skin Cancer ◽  
2017 ◽  
Vol 31 (3) ◽  
pp. 222-226
Author(s):  
Aya TANAKA ◽  
Atsushi TANAMURA ◽  
Kuniko IKINAGA ◽  
Yukinobu NAKAGAWA ◽  
Eiji KIYOHARA ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Target Therapy ◽  
Molecular Target ◽  
Advanced Melanoma ◽  
Molecular Target Therapy
Sign in / Sign up

Export Citation Format

Share Document